Terbinafine transdermal - Crescita Therapeutics
Alternative Names: NRI 1002; Penecure; Transcellular antifungal - CrescitaLatest Information Update: 24 Oct 2021
At a glance
- Originator Nuvo Research
- Developer Crescita Therapeutics
- Class Amines; Antifungals; Naphthalenes; Skin disorder therapies; Small molecules
- Mechanism of Action Cell membrane modulators; Squalene monooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Onychomycosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Onychomycosis in USA (Transdermal, Liquid)
- 17 Aug 2015 Terbinafine transdermal is still in preclinical trials for Onychomycosis in USA (http://www.nuvoresearch.com/products/pipeline/)
- 11 Aug 2015 Terbinafine transdermal - Nuvo Research is available for licensing as of 11 Aug 2015. http://www.nuvoresearch.com